Quoin Pharmaceuticals, Ltd.
QNRXDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
QNRX Earnings Report
EPS Est: $-1.83 | FQ end 2026-06
How QNRX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
QRX003, 4% Lotion | Phase 3 | Netherton Syndrome | - | - |
QRX003-2% Lotion | Phase 3 | Netherton Syndrome | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Quoin Pharmaceuticals, Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Quoin Pharmaceuticals, Ltd.'s (QNRX) pipeline across Phase 3. Its lead program is QRX003, 4% Lotion (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Quoin Pharmaceuticals, Ltd.'s next FDA catalyst?→
Quoin Pharmaceuticals, Ltd.'s (QNRX) next tracked catalyst is a Phase 3 expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track QNRX biotech catalysts?→
Add QNRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Quoin Pharmaceuticals, Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.